Infraredx Leadership

Dr. James E. Muller has served as Chief Medical Officer and Chairman of the Board of Infraredx since 2011. Dr. Muller’s interest in the causation of coronary events began in 1985 with the discovery of the morning increase of heart attacks. This led to a series of studies on the triggers of coronary events that, together with observations by other investigators, led to formulation of the concept of a “vulnerable” coronary plaque. In 1989, with Drs. Tofler and Stone, Dr. Muller published an article in CIRCULATION defining vulnerable plaques as those at high likelihood of rupture. In 1998, he founded Infraredx to develop spectroscopic technology to identify lipid core plaques, which are suspected to be vulnerable plaques. In 2005, he resigned from his position as Professor of Medicine at the Harvard Medical School to serve as CEO of Infraredx during the development of the scientific foundation of the lipid core plaque instrument. He is the author of over 300 manuscripts related to coronary artery disease, the leading cause of death in the developed world.

Mr. Southard joined InfraReDx as president and chief executive officer in early 2011, bringing more than 40 years of sales, marketing and leadership experience to the company. Most recently, he was chief executive officer of Zonare Medical Systems, a company focused on developing and marketing premium performance ultrasound imaging systems. From 1996 to 2004, Mr. Southard served as president of Datascope Corp., a global manufacturing and distribution company for medical capital equipment and disposable products. Prior to that, he was vice president of sales and marketing for Elscint Inc., a worldwide supplier of diagnostic medical equipment, president and chief executive officer of Serviscope Corp., a venture-backed supplier of cost-effective maintenance service and other cost-containment products to the medical imaging industry, and vice president of sales and marketing at Toshiba Medical Systems, Inc., where he oversaw U.S. medical operations. From 1981 to 1989, Mr. Southard worked at Philips Medical Systems, Inc., where he joined as eastern zone sales manager and rose to vice president of sales. He began his career at IBM, spending ten years at the company in sales and marketing positions of increasing responsibility. Mr. Southard holds a B.S. in chemistry from the University of Alabama and an Executive MBA from Babson College.

Dr. James E. Muller has served as Chief Medical Officer and Chairman of the Board of Infraredx since 2011. Dr. Muller’s interest in the causation of coronary events began in 1985 with the discovery of the morning increase of heart attacks. This led to a series of studies on the triggers of coronary events that, together with observations by other investigators, led to formulation of the concept of a “vulnerable” coronary plaque. In 1989, with Drs. Tofler and Stone, Dr. Muller published an article in CIRCULATION defining vulnerable plaques as those at high likelihood of rupture. In 1998, he founded Infraredx to develop spectroscopic technology to identify lipid core plaques, which are suspected to be vulnerable plaques. In 2005, he resigned from his position as Professor of Medicine at the Harvard Medical School to serve as CEO of Infraredx during the development of the scientific foundation of the lipid core plaque instrument. He is the author of over 300 manuscripts related to coronary artery disease, the leading cause of death in the developed world.

Dr. James E. Muller has served as Chief Medical Officer and Chairman of the Board of Infraredx since 2011. Dr. Muller’s interest in the causation of coronary events began in 1985 with the discovery of the morning increase of heart attacks. This led to a series of studies on the triggers of coronary events that, together with observations by other investigators, led to formulation of the concept of a “vulnerable” coronary plaque. In 1989, with Drs. Tofler and Stone, Dr. Muller published an article in CIRCULATION defining vulnerable plaques as those at high likelihood of rupture. In 1998, he founded Infraredx to develop spectroscopic technology to identify lipid core plaques, which are suspected to be vulnerable plaques. In 2005, he resigned from his position as Professor of Medicine at the Harvard Medical School to serve as CEO of Infraredx during the development of the scientific foundation of the lipid core plaque instrument. He is the author of over 300 manuscripts related to coronary artery disease, the leading cause of death in the developed world.

Mr. Southard joined InfraReDx as president and chief executive officer in early 2011, bringing more than 40 years of sales, marketing and leadership experience to the company. Most recently, he was chief executive officer of Zonare Medical Systems, a company focused on developing and marketing premium performance ultrasound imaging systems. From 1996 to 2004, Mr. Southard served as president of Datascope Corp., a global manufacturing and distribution company for medical capital equipment and disposable products. Prior to that, he was vice president of sales and marketing for Elscint Inc., a worldwide supplier of diagnostic medical equipment, president and chief executive officer of Serviscope Corp., a venture-backed supplier of cost-effective maintenance service and other cost-containment products to the medical imaging industry, and vice president of sales and marketing at Toshiba Medical Systems, Inc., where he oversaw U.S. medical operations. From 1981 to 1989, Mr. Southard worked at Philips Medical Systems, Inc., where he joined as eastern zone sales manager and rose to vice president of sales. He began his career at IBM, spending ten years at the company in sales and marketing positions of increasing responsibility. Mr. Southard holds a B.S. in chemistry from the University of Alabama and an Executive MBA from Babson College.